Dashboard
Manage Tickers

RPRX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rare-disease-focused-ascendis-pharma-stock-falls-on-underwhelming-q2-earnings-guidance-cut
Rare Disease-Focused Ascendis Pharma Stock...
09/04/2024 13:09:44

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million d...

Core News & Articles
Ascendis Pharma Subsidiary Enters $150M Ca...
09/03/2024 21:14:07

jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation
Jim Cramer: This Financial Stock Is A Buy,...
08/16/2024 13:28:17

Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."

goldman-sachs-maintains-buy-on-royalty-pharma-raises-price-target-to-51
Goldman Sachs Maintains Buy on Royalty Pha...
08/14/2024 11:10:42

Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50...

royalty-pharma-shares-are-trading-lower-after-the-company-reported-worse-than-expected-q2-financial-results
Royalty Pharma shares are trading lower af...
08/08/2024 14:45:45

royalty-pharma-q2-adj-096-misses-099-estimate-sales-53700m-miss-62826m-estimate
Royalty Pharma Q2 Adj $0.96 Misses $0.99 E...
08/08/2024 11:03:47

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.9...

morgan-stanley-maintains-overweight-on-royalty-pharma-raises-price-target-to-51
Morgan Stanley Maintains Overweight on Roy...
07/11/2024 17:16:39

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...

wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts Spotl...
06/12/2024 13:15:52

royalty-pharma-prices-offering-of-15b-of-senior-unsecured-notes
Royalty Pharma Prices Offering Of $1.5B Of...
06/03/2024 21:18:40

The offering is expected to close on June 10, 2024. Royalty Pharma intends to use the net proceeds from the Notes for general c...

ubs-downgrades-royalty-pharma-to-neutral-announces-28-price-target
UBS Downgrades Royalty Pharma to Neutral, ...
06/03/2024 15:50:14

UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:RPRX) from Buy to Neutral and announces $28 price target.

why-is-agios-pharmaceuticals-stock-trading-higher-on-tuesday
Why Is Agios Pharmaceuticals Stock Trading...
05/28/2024 17:00:41

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 mi...

Core News & Articles
Royalty Pharma Acquires Interest In Agios ...
05/28/2024 11:17:29

heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-uncertainty-analysts-observe
Heart Disease-Focused Cytokinetics Operati...
05/23/2024 18:30:40

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's comme...

Core News & Articles
Cytokinetics And Royalty Pharma Enter Fund...
05/22/2024 20:02:52

Core News & Articles
Royalty Pharma To Acquire Royalties And Mi...
05/09/2024 11:20:42

Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalt...

royalty-pharma-sees-fy24-portfolio-receipts-of-26b---27b
Royalty Pharma Sees FY24 Portfolio Receipt...
05/09/2024 11:05:34

royalty-pharma-q1-sales-56800m-miss-66322m-estimate
Royalty Pharma Q1 Sales $568.00M Miss $663...
05/09/2024 11:02:34

Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $568.00 million which missed the analyst consensus estimate of $663.22...

amgen-reports-better-than-expected-q1-results-50m-milestone-payment
Amgen Reports Better-Than-Expected Q1 Resu...
05/02/2024 21:44:40

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company s...

Core News & Articles
Arrowhead Pharmaceuticals Earns $50M Miles...
05/02/2024 20:39:45

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma ...

b-of-a-securities-maintains-buy-on-royalty-pharma-lowers-price-target-to-38
B of A Securities Maintains Buy on Royalty...
04/12/2024 12:01:57

B of A Securities analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION